首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1566177

免疫学市场规模、份额、成长分析、按药物类别、按疾病适应症、按分销管道、按地区 - 行业预测，2024-2031 年

Immunology Market Size, Share, Growth Analysis, By Drug Class, By Disease Indication, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月01日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球免疫学市场规模为958亿美元，从2023年的1,074.9亿美元成长到2031年的2,699.6亿美元，复合年增长率预计将维持在12.20%。

全球免疫学市场是一个快速变化的医疗保健和製药领域，专注于开拓各种免疫相关疾病的创新治疗方法和诊断方法，包括自体免疫疾病、癌症、过敏和感染疾病，这就是我工作的领域。由于这些疾病盛行率不断上升，对有效免疫疗法的需求正在迅速增加。生物技术和分子生物学的最新进展正在促进标靶免疫疗法的创建并推动市场成长。然而，也存在阻碍治疗方法广泛使用的重大挑战，包括飙升的治疗费用、严格的法规环境和复杂的保险报销框架。此外，新兴国家对尖端治疗的认识和获取有限可能会限制市场扩张。主要障碍包括更好地了解疾病机制、识别生物标记以进行更精确的患者分层以及开发个人化免疫疗法，所有这些都与免疫系统的复杂性有关，它与其他身体过程的相互作用错综复杂地交织在一起。然而，基因组和蛋白质组技术的进步以及对免疫调节的掌握程度的提高为未来提供了充满希望的机会。精准医学的兴起以及将免疫策略与其他治疗方法结合的可能性正在增加专业治疗的前景。总体而言，全球免疫学市场面临各种挑战，但应对这些挑战并利用创新机会可以带来免疫相关疾病治疗的变革性进展。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

AbbVie, Inc.（US）
Janssen Global Services, LLC（US）
Eli Lilly and Company（US）
Novartis AG（Switzerland）
Pfizer Inc.（US）
Bristol-Myers Squibb Company（US）
Merck Sharp & Dohme Corp.（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Amgen Inc.（US）
Astellas Pharma Inc.（Japan）
UCB SA（Belgium）
Sanofi（France）
Gilead Sciences, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Teva Pharmaceutical Industries Ltd.（Israel）
Takeda Pharmaceutical Company Limited（Japan）
Horizon Therapeutics plc（Ireland）
Aimmune Therapeutics, Inc.（US）
Celgene Corporation（US）
Incyte Corporation（US）
Boehringer Ingelheim GmbH（Germany）
Abbott Laboratories（US）

简介目录

Product Code: SQMIG35H2245

Global Immunology Market size was valued at USD 95.8 billion in 2022 and is poised to grow from USD 107.49 billion in 2023 to USD 269.96 billion by 2031, growing at a CAGR of 12.20% during the forecast period (2024-2031).

The global immunology market is a rapidly changing segment within the healthcare and pharmaceutical sectors, focused on developing innovative therapies and diagnostics for various immune-related disorders, such as autoimmune diseases, cancer, allergies, and infectious diseases. Driven by the rising prevalence of these conditions, there is an urgent demand for effective immunological treatments. Recent advancements in biotechnology and molecular biology have facilitated the creation of targeted immunotherapies, propelling market growth. However, the sector also faces significant challenges, including high treatment costs, stringent regulatory environments, and complex reimbursement frameworks that impede the widespread adoption of therapies. Furthermore, limited awareness and access to cutting-edge treatments in developing regions can restrict market expansion. Key hurdles include the need for deeper understanding of disease mechanisms, the identification of biomarkers for more accurate patient stratification, and the development of personalized immunotherapies, all compounded by the intricate nature of the immune system and its interactions with other bodily processes. Nevertheless, promising opportunities lie ahead, driven by advancements in genomic and proteomic technologies and a growing mastery of immune regulation. The rise of precision medicine and the potential integration of immunological strategies with other treatment modalities enhance prospects for specialized interventions. Overall, while the global immunology market confronts various challenges, addressing these issues and leveraging opportunities for innovation can lead to transformative advancements in the treatment of immune-related disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immunology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immunology Market Segmental Analysis

Global Immunology Market is segmented by Drug Class, Disease Indication, Distribution Channel, and region. Based on Drug Class, the market is segmented into Monoclonal Antibody, Immunosuppressants, Fusion Proteins, Others. Based on Disease Indication, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Immunology Market

The rapid advancements in biotechnology serve as a crucial market driver for the Global Immunology market, revolutionizing treatment options for immune-related disorders. With the introduction of novel biologics and targeted therapies, such as the FDA-approved bimekizumab for psoriasis and psoriatic arthritis, the therapeutic landscape is witnessing transformative shifts. These innovations not only offer superior efficacy compared to traditional treatments but also enhance patient outcomes significantly. As the demand for effective and tailored therapies rises, the integration of cutting-edge biotechnological developments will continue to propel growth in the immunology sector, fostering further research and investment in this dynamic field.

Restraints in the Global Immunology Market

The global immunology market faces considerable restraints due to the high costs associated with immunological therapies. The intricate processes involved in the development and manufacturing of biologics and targeted therapies contribute to elevated production costs, which are subsequently passed on to patients and healthcare systems. This financial burden restricts access to these innovative treatment options, particularly in developing regions where healthcare budgets are limited. Moreover, the persistent challenge of affordability stifles broader adoption of immunological interventions, hindering advancements in patient care and impeding market growth. As a result, addressing these economic barriers is crucial for the future expansion of the immunology sector.

Market Trends of the Global Immunology Market

The global immunology market is experiencing a significant shift towards personalized medicine, driven by advancements in biomarker development. Companies and researchers are increasingly investing in identifying specific biomarkers that can stratify patient populations, allowing for tailored immunotherapy approaches. This trend not only enhances treatment efficacy but also minimizes adverse reactions by ensuring that patients receive therapies tailored to their unique biological profiles. The growing demand for precision medicine, combined with technological innovations and regulatory support, positions personalized immunology therapies as a pivotal area of growth in the market, promising enhanced patient outcomes and a more targeted approach to immunological diseases.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Immunology Market by Drug Class

Market Overview
Monoclonal Antibody
Immunosuppressants
Fusion Proteins
Others

Immunology Market by Disease Indication

Market Overview
Rheumatoid Arthritis
Psoriatic Arthritis
Plaque Psoriasis
Ankylosing Spondylitis
Inflammatory Bowel Disease
Prophylaxis of Organ Rejection
Others

Immunology Market by Distribution Channel

Market Overview
Offline Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Online Channel

Immunology Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

AbbVie, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Global Services, LLC (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck Sharp & Dohme Corp. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aimmune Therapeutics, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments